Definitive Healthcare Corp. (NASDAQ:DH) Receives $2.77 Average PT from Analysts

Definitive Healthcare Corp. (NASDAQ:DH) has been given an average recommendation of “Hold” by the eight analysts that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $2.7667.

Several research firms have weighed in on DH. Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Stephens reduced their target price on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th. Canaccord Genuity Group reduced their target price on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating for the company in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. Finally, Barclays reduced their target price on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research note on Monday, March 30th.

Definitive Healthcare Price Performance

Definitive Healthcare stock opened at $0.81 on Wednesday. The stock has a market capitalization of $85.25 million, a price-to-earnings ratio of -0.50, a PEG ratio of 70.62 and a beta of 1.34. Definitive Healthcare has a 52-week low of $0.81 and a 52-week high of $4.70. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.75 and a current ratio of 1.75. The stock’s 50 day moving average price is $1.05 and its two-hundred day moving average price is $1.89.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $55.93 million during the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, equities analysts predict that Definitive Healthcare will post 0.01 earnings per share for the current year.

Institutional Trading of Definitive Healthcare

Several large investors have recently made changes to their positions in DH. Goldman Sachs Group Inc. grew its stake in shares of Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after buying an additional 7,404,363 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Definitive Healthcare in the 2nd quarter valued at about $4,247,000. Inspire Investing LLC grew its stake in shares of Definitive Healthcare by 505.7% in the 4th quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock valued at $2,006,000 after buying an additional 583,562 shares during the period. Millennium Management LLC grew its stake in shares of Definitive Healthcare by 230.9% in the 4th quarter. Millennium Management LLC now owns 332,087 shares of the company’s stock valued at $953,000 after buying an additional 231,743 shares during the period. Finally, Jane Street Group LLC grew its stake in shares of Definitive Healthcare by 212.4% in the 2nd quarter. Jane Street Group LLC now owns 328,410 shares of the company’s stock valued at $1,281,000 after buying an additional 223,296 shares during the period. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.